Business, Stock markets, Commodities, Currencies Business | The Guardian
US Federal Reserve chair Jerome Powell said the US is ‘getting back on a disinflationary path,’ minutes of Fed’s June meeting due later todayGSK has bought the full rights to develop, make and sell mRNA vaccines for flu and Covid-19 from Germany’s CureVac.The UK’s second-biggest drugmaker is paying €400m upfront and up to an additional €1.05bn to the biotech firm, which was founded in Tübingen in southwest Germany in 2000. The two companies have restructured their existing collaboration into a new licensing agreement.We are excited about our flu/Covid-19 programmes and the opportunity to develop best-in-class mRNA vaccines to change the standard of care. With this new agreement, we will apply GSK’s capabilities, partnerships and intellectual property to CureVac’s technology, to deliver these promising vaccines at pace.The collaboration with GSK has been instrumental in developing promising, late clinical-stage vaccine candidates, leveraging our proprietary mRNA platform. This new licensing agreement puts us in a strong financial position and enables us to focus on efforts in building a strong R&D pipeline. Continue reading…
US Federal Reserve chair Jerome Powell said the US is ‘getting back on a disinflationary path,’ minutes of Fed’s June meeting due later today
GSK has bought the full rights to develop, make and sell mRNA vaccines for flu and Covid-19 from Germany’s CureVac.
The UK’s second-biggest drugmaker is paying €400m upfront and up to an additional €1.05bn to the biotech firm, which was founded in Tübingen in southwest Germany in 2000. The two companies have restructured their existing collaboration into a new licensing agreement.
We are excited about our flu/Covid-19 programmes and the opportunity to develop best-in-class mRNA vaccines to change the standard of care. With this new agreement, we will apply GSK’s capabilities, partnerships and intellectual property to CureVac’s technology, to deliver these promising vaccines at pace.
The collaboration with GSK has been instrumental in developing promising, late clinical-stage vaccine candidates, leveraging our proprietary mRNA platform. This new licensing agreement puts us in a strong financial position and enables us to focus on efforts in building a strong R&D pipeline.
